Daiichi Sankyo shutters another R&D center in an ongoing global overhaul
Daiichi Pharma is closing another R&D division. A month after the Japanese pharma put out the word that it was closing a research facility in India and axing 170 staffers, Daiichi says it will now shutter a research hub in Japan with 150 investigators and transfer the work to other units.
Asubio Pharma has been the discovery engine at Daiichi, based in Kobe and focused on psychiatric and neurological diseases, immune and inflammatory diseases and regenerative medicine.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.